Leqvio and Progesterone HRT: Is It Safe to Take Them Together?

The Short Answer: No Pharmacokinetic Clash, One Pharmacodynamic Caution

Inclisiran (brand name Leqvio) and progesterone HRT do not interact through shared liver enzymes or drug transporters. Inclisiran is a small interfering RNA (siRNA) molecule that works inside hepatocytes and is broken down by endogenous nucleases, not by cytochrome P450 enzymes or P-glycoprotein (P-gp). Progesterone is metabolized primarily by CYP3A4 and CYP2C19, pathways that inclisiran simply never touches.

The one real caution is pharmacodynamic: oral micronized progesterone (Prometrium 200 mg taken at bedtime) has a documented sedative effect through GABA-A receptor modulation by its metabolite allopregnanolone. If you are also taking any other CNS-depressant medication at night, that sedation can add up. Inclisiran itself is not sedating, but this is a good time to audit your full medication list with your prescriber.

How Inclisiran Works in Your Body

Mechanism of Action

Inclisiran is a double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which targets it specifically to hepatocytes. Once inside the cell, it is loaded into the RNA-induced silencing complex (RISC) and directs cleavage of messenger RNA for PCSK9. PCSK9 mRNA is reduced by roughly 70 percent, causing LDL receptors to stay on the hepatocyte surface longer and clear more LDL cholesterol from the blood.

Why CYP Interactions Do Not Apply

Because inclisiran acts intracellularly through RNA interference rather than through protein-binding pharmacology, it bypasses the CYP enzyme system entirely. The FDA prescribing information for inclisiran states that inclisiran is not a substrate, inducer, or inhibitor of CYP enzymes or drug transporters including P-gp, BCRP, OATP1B1, OATP1B3, OCT1, or MRP2. This is a meaningful difference from the older PCSK9 inhibitors (evolocumab, alirocumab), which are monoclonal antibodies with their own interaction profile.

Dosing Schedule in Context

Inclisiran is given as a 284 mg subcutaneous injection at baseline, again at three months, then every six months. The ORION-10 trial showed a time-averaged LDL-C reduction of 52 percent versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD). Because you only receive two to three injections per year, the question of daily drug-drug interactions that preoccupy many oral medications simply does not apply in the same way.

How Progesterone HRT Works in Your Body

Forms of Progesterone Matter

Not all progestogens are the same, and the distinction matters for this conversation.

• Oral micronized progesterone (Prometrium, bioidentical): Absorbed through the gut, undergoes first-pass hepatic metabolism, generates neurosteroid metabolites including allopregnanolone. This is the form most associated with sedation.
• Vaginal progesterone (Crinone gel, Utrogestan vaginal): Primarily local uterine effect; systemic levels and sedation risk are much lower.
• Synthetic progestins (medroxyprogesterone acetate, norethindrone, levonorgestrel, drospirenone): Structurally different from bioidentical progesterone; CYP3A4 metabolism is still involved, but the neurosteroid sedation profile differs substantially.

The Menopause Society (formerly NAMS) 2022 Position Statement distinguishes oral micronized progesterone from synthetic progestins because of its more favorable metabolic and sleep profile, and this distinction also defines which progesterone form carries the sedation caution with inclisiran.

CYP3A4 Metabolism and What It Means for Women

Progesterone is a CYP3A4 substrate. Endogenous and exogenous estrogen can upregulate CYP3A4, which means progesterone clearance may be slightly faster in high-estrogen states such as the follicular phase or when exogenous estrogen is co-administered, but this is a minor physiological effect rather than a clinically actionable drug interaction. Inclisiran does not touch this pathway at all.

The One Interaction That Is Real: Additive Sedation

What Allopregnanolone Does

When you take oral micronized progesterone, your gut and liver convert it to allopregnanolone (3-alpha, 5-alpha-tetrahydroprogesterone). This neurosteroid is a positive allosteric modulator of GABA-A receptors, producing sedation, anxiolysis, and, in some women, dizziness or even cognitive blurring the next morning (colloquially called a "progesterone hangover"). This is not an adverse effect of inclisiran, but any woman who is already experiencing post-dose fatigue from another medication should be aware that oral progesterone adds to that burden.

Inclisiran and Sedation: The Evidence

Inclisiran itself is not classified as a CNS depressant. In the ORION-11 trial, adverse events related to CNS depression were not reported at rates above placebo. The injection-site reactions (mild erythema, pain, or nodule formation reported in 8.2 percent of inclisiran patients versus 2.9 percent on placebo) are the dominant side effects, not sedation.

A Practical Framework for Women Taking Both

For women using oral micronized progesterone at bedtime alongside inclisiran:

1. Schedule progesterone at night. This is already standard practice, and the sedative effect is then an advantage rather than a nuisance.
2. Audit the full medication list at the time of the inclisiran injection. Because injections are infrequent, this is a natural window to review every co-medication for sedation burden (antihistamines, gabapentin, benzodiazepines, low-dose naltrexone, or antidepressants).
3. Report morning grogginess lasting beyond two hours. This may signal that your progesterone dose or form needs adjustment rather than any problem with inclisiran.
4. Do not skip either medication. Cardiovascular risk in postmenopausal women is real. Women account for 45 percent of cardiovascular deaths in the United States annually, and the gap in LDL-lowering treatment between men and women remains documented.

Life-Stage Considerations: Who Is Most Likely to Need Both?

Perimenopause

In perimenopause, LDL cholesterol rises as estrogen levels decline. LDL-C increases by approximately 10 to 14 percent during the menopausal transition, even before the final menstrual period. Women in this stage may be starting progesterone HRT for vasomotor symptoms or cycle regulation while simultaneously seeing their lipid panel worsen. Statin therapy is typically first-line, and inclisiran is reserved for those who cannot tolerate statins or who need additional LDL lowering on top of maximum statin therapy.

If you are perimenopausal, still menstruating irregularly, and your cardiologist proposes inclisiran, a conversation about contraception is required (see the pregnancy section below).

Post-Menopause

This is the population most likely to need both drugs simultaneously. Post-menopausal women with familial hypercholesterolemia (FH) or established ASCVD who are also using HRT for symptom control or bone protection represent the clearest overlap. Familial hypercholesterolemia affects approximately 1 in 250 people, and women with FH enter higher cardiovascular risk after menopause because the estrogen-protective effect is lost. Inclisiran is FDA-approved specifically for this population.

Reproductive Years and PCOS

Women of reproductive age are rarely candidates for inclisiran because statin therapy is generally the standard of care for hyperlipidemia in this group. Women with PCOS often have atherogenic dyslipidemia (elevated triglycerides, low HDL, and small dense LDL), but inclisiran targets LDL-C reduction rather than triglyceride or HDL management, so its utility in PCOS specifically is limited. If a young woman with homozygous FH does need inclisiran, contraception is mandatory (see below).

Who This Drug Combination Is Right For, and Who Should Pause

Right For

• Post-menopausal women with heterozygous FH or ASCVD on maximally tolerated statin therapy, still not at LDL goal, who also use progesterone HRT for uterine protection alongside systemic estrogen
• Women with statin intolerance who need an alternative LDL-lowering strategy and who also use cyclic or continuous progesterone as part of their HRT regimen
• Women for whom the bedtime sedation from oral micronized progesterone is already tolerated and accepted as a sleep aid

Not Right For

• Pregnant women (see next section)
• Women trying to conceive without strong contraception in place, given the teratogenicity signal in animal studies
• Women with LDL elevation driven primarily by triglycerides, VLDL, or HDL-C issues rather than LDL-C, where other agents are more appropriate
• Women whose "HRT" includes only topical vaginal estrogen without systemic progesterone, because the interaction question does not apply

Pregnancy, Lactation, and Contraception: Required Reading

Inclisiran is contraindicated in pregnancy. This is not a theoretical caution.

Animal Data and the Human Evidence Gap

Animal reproductive toxicology studies with inclisiran showed embryo-fetal toxicity at exposures below the human clinical dose. There are no adequate and well-controlled studies in pregnant women. Given the mechanism of action (gene silencing in hepatocytes), the potential for unintended fetal effects cannot be dismissed. The FDA label carries a clear contraindication in pregnancy.

Women who could become pregnant must use effective contraception during inclisiran therapy. Because inclisiran is dosed every six months, contraception must be maintained throughout the treatment period. The FDA label does not specify a washout window post-discontinuation before conception is safe; current practice is to discuss this with your prescriber and stop inclisiran well before any planned pregnancy attempt.

Lactation

There are no data on inclisiran in human breast milk, animal milk transfer, or effects on the breastfed infant. Given the high molecular weight of the GalNAc-siRNA conjugate and typical patterns for large molecule drugs, significant systemic transfer to breast milk is considered unlikely, but "unlikely" is not the same as "studied." The FDA label advises that the benefits of breastfeeding should be considered alongside the mother's clinical need and the potential exposure to the infant. In practical terms, most women requiring inclisiran (post-menopausal or older reproductive-age women with severe hypercholesterolemia) are not breastfeeding, but this should be confirmed.

Progesterone HRT in Pregnancy

Systemic progesterone HRT formulations (oral micronized progesterone, synthetic progestins in HRT doses) are not indicated for use in pregnancy for cholesterol management. Vaginal progesterone is used in specific obstetric contexts (luteal support in IVF, short cervix) under direct obstetric supervision, which is a completely different clinical scenario. If you are using HRT and discover you are pregnant, discuss stopping HRT immediately with your clinician.

PCSK9 Biology, Lipid Goals, and the Evidence Base in Women

The Sex-Specific Evidence Gap

Women have been under-represented in cardiovascular outcomes trials throughout the history of lipid research. In the ORION-10 trial, women made up approximately 28 percent of participants, which is an improvement over older statin trials but still not parity. The sex-disaggregated data from ORION-10 and ORION-11 showed consistent LDL-C reductions in women, but the statistical power to detect sex differences in hard cardiovascular endpoints within inclisiran trials specifically does not yet exist.

The American Heart Association 2022 Guideline on Cardiovascular Risk Reduction in Women explicitly notes that women are undertreated for LDL-C, and that pregnancy-associated conditions (preeclampsia, gestational diabetes, preterm birth) confer additional lifetime cardiovascular risk. This means that women arriving at inclisiran candidacy often have a higher-than-recognized baseline risk.

LDL Targets in Women on HRT

Oral estrogen raises triglycerides and can slightly raise LDL in some formulations; transdermal estradiol has a more neutral or mildly beneficial lipid effect. Progesterone itself has a largely neutral lipid effect when used as bioidentical oral micronized progesterone, whereas some synthetic progestins (particularly those with androgenic activity such as norethindrone) can partially blunt the HDL-raising effect of estrogen. None of these HRT lipid effects are large enough to affect inclisiran dosing, but they are worth tracking on your next lipid panel after starting HRT.

Monitoring and Practical Prescriber Coordination

The separation of prescribers (cardiologist or lipidologist for inclisiran, OB-GYN or menopause specialist for HRT) creates the most common failure point. Both prescribers need your complete medication list.

At each inclisiran injection visit (roughly every six months):

• Confirm your current HRT formulation and dose
• Review the full list of any CNS-active medications for sedation burden if you use oral progesterone at night
• Check a fasting lipid panel (LDL-C, non-HDL-C, triglycerides)
• Confirm pregnancy status if you are not post-menopausal
• Document injection-site skin response; mild nodularity resolves without treatment

At your HRT review (annually or after dose changes):

• Share your inclisiran dosing schedule with your menopause specialist
• Note any change in sleep quality or morning grogginess since starting oral progesterone, since the progesterone dose can be adjusted if the hangover effect is new
• Discuss lipid panel trends, since your HRT type can influence triglycerides and HDL even if inclisiran is handling LDL-C

"Women with ASCVD on HRT represent a carefully selected group where cardiovascular benefit is being weighed thoughtfully," states the Menopause Society 2022 Position Statement, noting that HRT initiated within ten years of menopause onset or before age sixty does not carry the same cardiovascular risk profile as initiation in older post-menopausal women.

The ACC/AHA 2018 Cholesterol Guideline places PCSK9 inhibitors (including siRNA-based agents such as inclisiran) as adjunct therapy for very high-risk patients with LDL-C above 70 mg/dL on maximally tolerated statin therapy, which is the threshold at which a woman on HRT would likely encounter a conversation about inclisiran.

Injection-Site Reactions and Female Skin Considerations

Inclisiran is given subcutaneously in the abdomen, upper arm, or thigh. The injection-site reaction rate in clinical trials was higher in inclisiran versus placebo (8.2 versus 2.9 percent), with reactions generally mild and self-limited. Women with thinner subcutaneous fat in the abdominal area (common after menopause due to body composition shifts) may experience slightly more local nodularity. Rotating injection sites and confirming correct needle angle with your administering clinician reduces this.

Oral micronized progesterone does not affect skin or subcutaneous tissue in a way that would change injection-site tolerance.